GO:0033002 muscle cell proliferation: Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0033002 (muscle cell proliferation) is defined as the expansion of a muscle cell population by cell division, and its synonym is myocyte proliferation.
• Muscle cell proliferation is a tightly regulated process that underlies vascular remodeling, cardiac development, and skeletal muscle regeneration.
• Dysregulated muscle cell proliferation is a hallmark of atherosclerosis, pulmonary arterial hypertension, and other vascular proliferative diseases [1,3,4,5,6].
• Key molecular drivers include glycolytic enzymes, Skp2, S1PR2, and micropeptides such as miPEP31, which modulate smooth muscle cell proliferation through Akt/mTOR and RhoA/ROCK1 signaling [4,5,7,8].
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal interrogation of genes controlling muscle cell proliferation.
• Understanding muscle cell proliferation at the molecular level informs therapeutic strategies for cardiovascular and musculoskeletal disorders [1,6].
Description
Muscle cell proliferation, formally annotated as GO:0033002, is the biological process by which a population of muscle cells expands through cell division. This process is fundamental to the development, growth, and repair of cardiac, skeletal, and smooth muscle tissues, and its dysregulation contributes to a wide range of human pathologies [2,6]. In the vasculature, excessive proliferation of vascular smooth muscle cells (VSMCs) drives neointimal hyperplasia and atherosclerotic plaque progression, making it a central focus of cardiovascular research [1,4,5]. In the heart, cardiomyocyte proliferation is critical for prenatal heart growth and is a major target for regenerative medicine. In skeletal muscle, satellite cell proliferation is required for postnatal muscle growth and regeneration after injury. Given its broad physiological and pathological relevance, muscle cell proliferation is a key area of investigation for researchers seeking to understand tissue homeostasis and to develop targeted therapies for proliferative vascular diseases, pulmonary hypertension, and atherosclerosis [3,6,7]. This article synthesizes authoritative QuickGO annotation data and verified PubMed literature to provide a research-grade overview of the mechanisms, genes, and experimental models associated with GO:0033002.
muscle cell proliferation At A Glance
| GO ID | GO:0033002 |
|---|---|
| GO term | muscle cell proliferation |
| Ontology | biological_process |
| Synonym | myocyte proliferation |
| Definition | The expansion of a muscle cell population by cell division. |
| Major function | Expansion of muscle cell populations during development, growth, and repair. |
| Related processes | Smooth muscle cell proliferation, cardiomyocyte proliferation, skeletal muscle satellite cell proliferation. |
| Disease relevance | Atherosclerosis, pulmonary arterial hypertension, vascular proliferative diseases, cardiac regeneration. |
What Is GO:0033002?
According to the Gene Ontology, GO:0033002 (muscle cell proliferation) is defined as the expansion of a muscle cell population by cell division. The term is synonymous with myocyte proliferation and falls under the biological_process ontology aspect. It encompasses the mitotic division of any muscle cell type, including smooth muscle cells, cardiac muscle cells, and skeletal muscle cells, leading to an increase in cell number rather than cell size (hypertrophy). This process is distinct from muscle cell differentiation and muscle cell hypertrophy, although it often occurs in concert with these processes during tissue remodeling and repair [2,6].
Why Is muscle cell proliferation Important in Cell Biology?
Muscle cell proliferation is critically important because it governs the cellular basis of muscle tissue growth, regeneration, and vascular remodeling. In blood vessels, abnormal proliferation of smooth muscle cells is a primary driver of atherosclerosis, restenosis after angioplasty, and pulmonary arterial hypertension, making it a prime therapeutic target [1,3,4,5,6]. In the heart, the limited proliferative capacity of cardiomyocytes after birth restricts cardiac regeneration, and understanding how to reactivate proliferation could revolutionize treatment of heart failure. In skeletal muscle, satellite cell proliferation is essential for muscle repair and is impaired in muscular dystrophies and aging. Thus, deciphering the molecular controls of GO:0033002 has broad implications for cardiovascular medicine, regenerative biology, and musculoskeletal health [2,6,7,8].
• Drives vascular remodeling and neointima formation in atherosclerosis and restenosis [1,4,5].
• Underlies pathological pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension [3,6].
• Is essential for prenatal cardiomyocyte expansion and heart development.
• Supports skeletal muscle satellite cell activation and regeneration after injury.
• Is a hallmark of vascular proliferative diseases and a target for antiproliferative therapies [4,7].
• Involves metabolic reprogramming, including increased glycolysis, to support rapid cell division.
• Is regulated by micropeptides and non-coding RNAs, offering novel therapeutic entry points.
• Dysregulation contributes to hypertension and vascular stiffness [5,8].
• Provides a model system for studying cell cycle control and signal transduction.
• Enables development of CRISPR-based disease models for drug discovery.
What Happens During muscle cell proliferation?
Initiation and Cell Cycle Entry
In simple terms: Muscle cells receive signals that tell them to start dividing.
Muscle cell proliferation begins when quiescent or differentiated muscle cells are stimulated by growth factors, cytokines, or mechanical stress to re-enter the cell cycle. In vascular smooth muscle cells, factors such as platelet-derived growth factor (PDGF) and angiotensin II promote the transition from G0 to G1 phase, a process that is dysregulated in atherosclerosis and hypertension [1,4,5]. In skeletal muscle, satellite cells are activated by injury signals to proliferate and subsequently differentiate. This initiation step is tightly controlled by cyclin-dependent kinases and their inhibitors, and its deregulation is a key event in vascular proliferative diseases.
Metabolic Reprogramming and Glycolysis
In simple terms: Dividing muscle cells switch their energy production to support rapid growth.
Proliferating muscle cells, particularly vascular smooth muscle cells, undergo metabolic reprogramming characterized by increased glycolysis. Glycolytic enzymes such as hexokinase 2 and lactate dehydrogenase A are upregulated to meet the biosynthetic demands of rapid cell division. This metabolic shift is not merely a consequence of proliferation but actively regulates it, as inhibition of glycolysis suppresses smooth muscle cell proliferation and neointimal formation. The interplay between metabolic pathways and cell cycle progression is an emerging area of research in vascular biology.
Signal Transduction Pathways
In simple terms: Specific molecular switches inside the cell turn on the proliferation program.
Multiple signaling cascades converge to drive muscle cell proliferation. The S1PR2 receptor mediates smooth muscle cell proliferation via Akt/mTOR and RhoA/ROCK1 pathways in atherosclerosis. The Skp2 ubiquitin ligase promotes proliferation by degrading cell cycle inhibitors such as p27, and its overexpression is linked to vascular lesion formation. Additionally, the micropeptide miPEP31 inhibits vascular smooth muscle cell proliferation by cooperating with the transcription factor Trps1, highlighting the role of non-canonical regulators. These pathways represent potential therapeutic targets for modulating GO:0033002 [5,7,8].
Mitosis and Population Expansion
In simple terms: The cell actually divides into two new muscle cells.
The culmination of muscle cell proliferation is mitosis, where a single muscle cell divides into two genetically identical daughter cells, leading to expansion of the muscle cell population. This step requires precise coordination of DNA replication, chromosome segregation, and cytokinesis. In the pig model, the dynamics of cardiomyocyte and muscle stem cell proliferation have been characterized, showing that proliferative capacity declines with age. In pathological conditions such as pulmonary hypertension, excessive mitosis of smooth muscle cells leads to vascular remodeling and increased pulmonary vascular resistance. Understanding the mitotic machinery in muscle cells is essential for developing antiproliferative therapies [6,7].
Key Genes Involved in GO:0033002 muscle cell proliferation
The following genes and proteins have been experimentally implicated in the regulation of muscle cell proliferation (GO:0033002) according to verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Skp2 | Ubiquitin ligase that degrades p27 and promotes cell cycle progression | Overexpression drives vascular smooth muscle cell proliferation; target for restenosis |
| S1PR2 | G-protein coupled receptor mediating Akt/mTOR and RhoA/ROCK1 signaling | Promotes smooth muscle cell proliferation in atherosclerosis |
| Trps1 | Transcription factor cooperating with miPEP31 | Inhibits vascular smooth muscle cell proliferation; potential therapeutic target |
| miPEP31 | Micropeptide encoded by a microRNA | Inhibits VSMC proliferation via Trps1; novel regulator |
| HK2 | Hexokinase 2, key glycolytic enzyme | Upregulated in proliferating VSMCs; supports metabolic reprogramming |
| LDHA | Lactate dehydrogenase A | Facilitates glycolytic flux in proliferating VSMCs |
| mTOR | Serine/threonine kinase in PI3K/Akt pathway | Central regulator of muscle cell proliferation and growth |
| RhoA | Small GTPase | Mediates S1PR2-driven proliferation via ROCK1 |
| ROCK1 | Rho-associated kinase | Effector of RhoA in smooth muscle cell proliferation |
| p27 (CDKN1B) | Cyclin-dependent kinase inhibitor | Degraded by Skp2 to permit cell cycle entry |
| PDGF | Platelet-derived growth factor | Stimulates VSMC proliferation in vascular injury |
| Angiotensin II | Vasoactive peptide | Promotes VSMC proliferation and hypertension |
| Ginsenoside Rb1 | Natural compound | Alleviates atherosclerosis by modulating VSMC proliferation and autophagy |
| Lipid droplets | Cellular organelles | Involved in pulmonary artery smooth muscle cell proliferation |
| Autophagy-related proteins | Autophagy machinery | Modulate VSMC proliferation in atherosclerosis |
| Cardiomyocyte proliferation markers (e.g., Ki67) | Proliferation markers | Used to assess cardiomyocyte proliferation in pig models |
How Is muscle cell proliferation Regulated?
Muscle cell proliferation is regulated by a complex network of extracellular signals, intracellular signaling pathways, and metabolic cues. Key regulatory nodes include the Akt/mTOR pathway, which integrates growth factor signals to promote protein synthesis and cell cycle progression. The RhoA/ROCK1 axis controls cytoskeletal dynamics and gene expression necessary for proliferation. The Skp2-p27 axis governs cell cycle entry by controlling the stability of cyclin-dependent kinase inhibitors. Metabolic regulation through glycolysis provides biosynthetic precursors and ATP for dividing cells. Additionally, non-coding RNAs and micropeptides such as miPEP31 add layers of post-transcriptional and translational control. In pulmonary hypertension, lipid droplet accumulation and altered autophagy contribute to dysregulated proliferation. These regulatory mechanisms are potential targets for therapeutic intervention in vascular proliferative diseases [1,3,4,5,7,8].
muscle cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| S1PR2 | Atherosclerosis | VSMC-specific knockout or overexpression in ApoE-/- mice |
| Skp2 | Restenosis, vascular proliferative disease | Smooth muscle cell-specific Skp2 knockout or transgenic mice |
| miPEP31/Trps1 | Hypertension, vascular remodeling | Knockout of miPEP31 or Trps1 in VSMCs |
| Glycolytic enzymes (HK2, LDHA) | Vascular proliferative diseases | Inducible knockout in smooth muscle cells |
| Lipid droplets | Pulmonary arterial hypertension | PASMC-specific manipulation in PAH models |
Atherosclerosis and Vascular Proliferative Diseases
Atherosclerosis is characterized by excessive proliferation and migration of vascular smooth muscle cells, leading to neointimal hyperplasia and plaque formation. Ginsenoside Rb1 has been shown to alleviate atherosclerosis by modulating VSMC proliferation, foam cell formation, and autophagy. The S1PR2 receptor mediates VSMC proliferation via Akt/mTOR and RhoA/ROCK1 pathways, and its inhibition reduces atherosclerotic lesion development. Glycolytic enzymes are upregulated in proliferating VSMCs and represent potential therapeutic targets for vascular proliferative diseases. Skp2 overexpression promotes VSMC proliferation and is associated with restenosis after angioplasty. These findings underscore the importance of GO:0033002 in cardiovascular pathology [1,4,5,7].
Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a devastating disease characterized by excessive proliferation of pulmonary artery smooth muscle cells (PASMCs), leading to vascular remodeling and right heart failure. Lipid droplets have been implicated in PAH pathogenesis by promoting PASMC proliferation. Smooth muscle cell hypertrophy, proliferation, migration, and apoptosis are all dysregulated in pulmonary hypertension, contributing to vascular obstruction. Targeting the proliferative component of PAH is a major therapeutic strategy, and understanding the molecular drivers of PASMC proliferation is critical for developing new treatments [3,6].
Cardiac Development and Regeneration
Cardiomyocyte proliferation is essential for prenatal heart growth, but this capacity is largely lost after birth in mammals. Studies in pig models have characterized the dynamics of cardiomyocyte and muscle stem cell proliferation, revealing a decline in proliferative activity with age. Reactivating cardiomyocyte proliferation is a major goal of cardiac regenerative medicine, and understanding the molecular brakes on this process could lead to novel therapies for heart failure. The signaling pathways that regulate cardiomyocyte proliferation overlap with those in smooth muscle cells, including Akt/mTOR and cell cycle regulators [5,7].
From muscle cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X drive smooth muscle cell proliferation in atherosclerosis? | VSMC-specific knockout or overexpression in ApoE-/- or LDLR-/- mice [1,5] |
| Does a point mutation in gene Y alter its pro-proliferative function? | CRISPR knock-in of point mutation in VSMCs or cardiomyocytes |
| Does gene Z regulate cardiomyocyte proliferation during development? | Cardiomyocyte-specific knockout or transgenic overexpression in mice or pigs |
| Can a tagged version of protein W reveal its interactome in proliferating muscle cells? | Knock-in of epitope tag (e.g., FLAG, HA) using CRISPR |
| Does overexpression of micropeptide miPEP31 inhibit VSMC proliferation? | Lentiviral overexpression in cultured VSMCs and in vivo |
| What is the role of glycolysis in VSMC proliferation? | Knockout of HK2 or LDHA in VSMCs and metabolic assays |
How to Study the muscle cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| EdU/BrdU incorporation | DNA synthesis | Quantification of proliferating VSMCs or cardiomyocytes [1,4] |
| Ki67 immunostaining | Cells in active cell cycle | Tissue sections from animal models [2,6] |
| RNA-seq | Global gene expression | Identify pathways upregulated during proliferation |
| Proteomics | Protein abundance and modifications | Discover regulators of VSMC proliferation |
| Immunofluorescence | Protein localization and cell morphology | Visualize proliferation markers in tissues [5,8] |
| CRISPR screen | Gene function on a genome-wide scale | Identify novel proliferation regulators [4,7] |
| Metabolic assays | Glycolysis and oxidative phosphorylation | Assess metabolic reprogramming in proliferating cells |
| Lineage tracing | Cell fate in vivo | Track smooth muscle cell expansion in disease models [2,6] |
Cell Proliferation Assays
Standard methods to measure muscle cell proliferation include BrdU or EdU incorporation, Ki67 staining, and MTT assays. These techniques quantify DNA synthesis and metabolic activity in proliferating cells. In the context of GO:0033002, they are used to assess the effects of genetic manipulations or drug treatments on VSMC or cardiomyocyte proliferation [1,4,5,7,8].
Transcriptomics and Proteomics
RNA sequencing (RNA-seq) and proteomics can identify global changes in gene expression and protein abundance during muscle cell proliferation. For example, RNA-seq of proliferating VSMCs has revealed upregulation of glycolytic enzymes and cell cycle regulators. Proteomic approaches can uncover post-translational modifications and protein-protein interactions that regulate proliferation.
Imaging and Lineage Tracing
Immunofluorescence and confocal microscopy allow visualization of proliferation markers and cellular morphology in muscle tissues. Lineage tracing using Cre-lox systems in mice can track the fate of proliferating muscle cells in vivo, providing insights into their contribution to tissue remodeling [2,6].
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout or activation screens can identify novel regulators of muscle cell proliferation. These unbiased approaches are powerful for discovering genes that either promote or suppress proliferation, and they can be combined with RNA-seq to elucidate mechanisms [4,7].
How CRISPR Can Be Used to Study GO:0033002 muscle cell proliferation
Knockout
CRISPR knockout is used to delete genes of interest in muscle cells to determine their necessity for proliferation. For example, knocking out S1PR2 or Skp2 in VSMCs can reduce proliferation and attenuate vascular lesion formation in mouse models [5,7]. Knockout of glycolytic enzymes such as HK2 can suppress VSMC proliferation by disrupting metabolic reprogramming. These models provide causal evidence for gene function in GO:0033002.
Point Mutation
CRISPR point mutation (base editing or prime editing) allows introduction of specific amino acid substitutions to dissect protein function. For instance, mutating phosphorylation sites in Skp2 or S1PR2 can reveal their role in proliferation signaling [5,7]. This approach is valuable for understanding how disease-associated mutations affect muscle cell proliferation.
Knock-in
Knock-in of reporter genes (e.g., GFP, luciferase) or epitope tags (e.g., FLAG, HA) enables visualization and biochemical analysis of proteins involved in muscle cell proliferation. Tagging endogenous miPEP31 or Trps1 can facilitate interaction studies and live-cell imaging. Knock-in of disease-relevant mutations can also model human vascular disorders.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression is used to increase gene expression and assess sufficiency for proliferation. Overexpression of Skp2 or S1PR2 promotes VSMC proliferation, while overexpression of miPEP31 inhibits it [5,7,8]. These models are useful for validating therapeutic targets and understanding gain-of-function mechanisms.
How EDITGENE Supports muscle cell proliferation Research
Researchers studying muscle cell proliferation-related genes often need to determine whether a candidate gene is causally involved in the proliferative process, and CRISPR-based models provide the most direct way to establish such causality. EDITGENE offers a comprehensive suite of services to support these investigations, from knockout and point mutation to knock-in and overexpression, as well as library screening and bioinformatics.
Contact EDITGENE today to design your custom CRISPR model for muscle cell proliferation research.
Frequently Asked Questions About muscle cell proliferation
What is GO:0033002?
GO:0033002 is the Gene Ontology term for muscle cell proliferation, defined as the expansion of a muscle cell population by cell division. It is synonymous with myocyte proliferation [2,6].
What genes are involved in muscle cell proliferation?
Key genes include S1PR2, Skp2, Trps1, miPEP31, HK2, LDHA, mTOR, RhoA, and ROCK1, among others [4,5,7,8].
How is muscle cell proliferation regulated?
It is regulated by signaling pathways such as Akt/mTOR and RhoA/ROCK1, cell cycle regulators like Skp2 and p27, metabolic reprogramming through glycolysis, and non-coding RNAs/micropeptides [4,5,7,8].
What diseases are associated with abnormal muscle cell proliferation?
Atherosclerosis, pulmonary arterial hypertension, restenosis, and vascular proliferative diseases are linked to dysregulated muscle cell proliferation [1,3,4,5,6].
How can I study muscle cell proliferation in the lab?
Common methods include EdU/BrdU incorporation, Ki67 staining, RNA-seq, proteomics, and CRISPR screens [1,2,4,7].
What is the role of Skp2 in muscle cell proliferation?
Skp2 is a ubiquitin ligase that degrades the cell cycle inhibitor p27, thereby promoting vascular smooth muscle cell proliferation and contributing to vascular lesion formation.
How does S1PR2 affect smooth muscle cell proliferation?
S1PR2 mediates smooth muscle cell proliferation via Akt/mTOR and RhoA/ROCK1 signaling pathways in atherosclerosis.
What is miPEP31 and how does it affect muscle cell proliferation?
miPEP31 is a micropeptide that inhibits vascular smooth muscle cell proliferation by cooperating with the transcription factor Trps1.
Can CRISPR be used to study muscle cell proliferation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect gene function in muscle cell proliferation [4,5,7,8].
What are the metabolic features of proliferating muscle cells?
Proliferating muscle cells, especially vascular smooth muscle cells, exhibit increased glycolysis, with upregulation of enzymes like hexokinase 2 and lactate dehydrogenase A.
Conclusion
Muscle cell proliferation (GO:0033002) is a fundamental biological process that drives tissue growth, repair, and pathological vascular remodeling. Its dysregulation is central to atherosclerosis, pulmonary arterial hypertension, and other proliferative diseases, making it a critical area of biomedical research [1,3,4,5,6]. Advances in CRISPR-based genome editing and functional genomics have provided powerful tools to dissect the molecular mechanisms governing muscle cell proliferation, from signaling pathways to metabolic reprogramming [4,5,7,8]. Continued research into this process promises to yield new therapeutic strategies for cardiovascular and musculoskeletal disorders.
References
- 1. Yuan HH et al.. 2025. Ginsenoside Rb1 alleviates atherosclerosis by modulating vascular smooth muscle cell proliferation, foam cell formation, and autophagy.. Phytomedicine 149:157503 PMID: 41237446
- 2. Yin B et al.. 2020. Dynamics of cardiomyocyte and muscle stem cell proliferation in pig.. Exp Cell Res 388(2):111854 PMID: 31954694
- 3. Huang B et al.. 2025. Role of lipid droplets in pulmonary arterial hypertension: focusing on pulmonary artery smooth muscle cell proliferation.. Lipids Health Dis 24(1):333 PMID: 41107943
- 4. Sarkar A et al.. 2024. Gamut of glycolytic enzymes in vascular smooth muscle cell proliferation: Implications for vascular proliferative diseases.. Biochim Biophys Acta Mol Basis Dis 1870(3):167021 PMID: 38216067
- 5. Ouyang J et al.. 2025. S1PR2 Mediates Smooth Muscle Cell Proliferation and Endothelial Cell Permeability via Akt/mTOR and RhoA/ROCK1 in Atherosclerosis.. J Biochem Mol Toxicol 39(6):e70351 PMID: 40495705
- 6. Tajsic T et al.. 2011. Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension.. Compr Physiol 1(1):295-317 PMID: 23737174
- 7. Bond M et al.. 2011. Proliferation unleashed: the role of Skp2 in vascular smooth muscle cell proliferation.. Front Biosci (Landmark Ed) 16(4):1517-35 PMID: 21196245
- 8. Jiang G et al.. 2025. miPEP31 inhibits the vascular smooth muscle cell proliferation via cooperation with transcription factor Trps1.. Clin Exp Hypertens 47(1):2561235 PMID: 40982340
